RNA, U7 small nuclear 43 pseudogeneGenealiases: RNU7-118P · U7.43
Q-omics provides the consensus-scored RNU7-43P profile across patient tissues and cancer cell-line models. RNU7-43P expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RNU7-43P is differentially expressed in 4, with the highest sampling consensus in KIRP. Additionally, RNU7-43P RNA expression shows 7,198 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight MESO, KIRP, and CCRCC as cancer lineages where RNU7-43P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU7-43P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU7-43P survival associations across molecular data types. RNU7-43P RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU7-43P RNA expression–survival associations across cancer types. High RNU7-43P expression shows unfavorable associations in MESO, COAD, BLCA, PAAD and KIRC, but favorable associations in BRCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .016). Together, the overview and detailed table identify MESO as the clearest survival context for RNU7-43P RNA expression.
This table summarizes RNU7-43P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for RNU7-43P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU7-43P shows lower tumor expression in KIRP and LUSC and higher tumor expression in KICH and CHOL. The KIRP box plot shows higher RNU7-43P RNA expression in normal versus tumor tissue (log2 FC = −0.559, t-test p = .011).
This table shows molecular features associated with RNU7-43P in patient tissues and cancer cell lines. In patient samples, RNU7-43P shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set.
